P
6.19
-0.29 (-4.48%)
| Previous Close | 6.48 |
| Open | 6.60 |
| Volume | 823,860 |
| Avg. Volume (3M) | 1,114,640 |
| Market Cap | 546,732,416 |
| Price / Sales | 5.64 |
| Price / Book | 2.72 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 |
| Profit Margin | -98.10% |
| Operating Margin (TTM) | -85.88% |
| Diluted EPS (TTM) | -1.29 |
| Quarterly Revenue Growth (YOY) | 5.50% |
| Total Debt/Equity (MRQ) | 21.81% |
| Current Ratio (MRQ) | 6.91 |
| Operating Cash Flow (TTM) | -42.70 M |
| Levered Free Cash Flow (TTM) | -23.09 M |
| Return on Assets (TTM) | -17.90% |
| Return on Equity (TTM) | -51.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Personalis, Inc. | Bullish | Bullish |
AIStockmoo Score
0.9
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.88 |
|
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 31.49% |
| % Held by Institutions | 46.11% |
| 52 Weeks Range | ||
| Median | 8.50 (37.32%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 08 Sep 2025 | 8.50 (37.32%) | Buy | 5.32 |
| 06 Aug 2025 | 8.50 (37.32%) | Buy | 4.41 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |